Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof

US11884722B2 · kind B2 · utility

Assignee

• JANSSEN BIOTECH, INC. · US

Inventors

• Ricardo Attar · Lawrenceville, US
• Francois Gaudet · Princeton, US
• Mark Tornetta · Collegeville, US
• Alexey Teplyakov · Spring House, US
• Mark Mendonca · Philadelphia, US
• Suzanne Edavettal · San Diego, US
• Kodandaram Pillarisetti · Spring House, US
• Nathan Majewski · Warrington, US
• Yingzhe Li · Dresher, US
• Leopoldo L. Luistro, III · Lansdale, US
• Diana Chin · Norwood, US

Key dates

• Filing date: Jan 20, 2023
• Grant date: Jan 30, 2024
• Expiry date: Jan 20, 2043

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.